Pam Klein, M.D.

Dr. Klein has more than 15 years of clinical and translational research experience in oncology drug development and has led programs spanning the pre-clinical stage to approval and beyond.

She is Principal of PMK BioResearch offering strategic consulting to all stages of biotech and Venture Capital. Klein was the CMO for Intellikine, where she successful built the clinical development organization bringing their early compounds from the lab to IND and then clinic. Intellikine was ultimately purchased by Takeda/Millenium. Prior to this, Klein was at Genentech holding positions of increasing responsibility, lastly Vice President, Development. While at Genentech, Klein led the HER, HEME and Apoptosis programs.

Klein has expertise incorporating diagnostics and surrogate markers into clinical programs. Prior to her work at Genentech, Klein was at The National Cancer Institute, where she built and ran the NCI-Navy Breast Center.

She earned her medical degree from Stritch School of Medicine, Loyola and completed her internal medicine at Cedar-Sinai receiving the Leo Rigler Award for Resident of the Year, and the Ben Newman Award for Most Humanistic Physician. She did a Medical Oncology Fellowship at the NCI serving as Chief Fellow and then completed an additional year in Cancer Genetics.